{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:56:59Z","timestamp":1794603419476,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["CA72851,CA181572,CA227602,CA214254,CA271443,and CA187956"],"award-info":[{"award-number":["CA72851,CA181572,CA227602,CA214254,CA271443,and CA187956"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2025,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cetuximab, an EGFR-targeting monoclonal antibody, provides beneficial yet limited clinical improvement in\n                    <jats:italic>KRAS<\/jats:italic>\n                    wild-type metastatic colorectal cancer (mCRC). While circRNA dysregulation has been implicated in various cancers, the role of circ-EGFR in response to EGFR-targeted therapy in mCRC remains largely unexplored. Here, we identified circ-EGFR as a promising predictive biomarker for cetuximab response. Clinically, we first determined that tissue-based circ-EGFR biomarker effectively stratified responders from non-responders to cetuximab in mCRC, with an Area under the Curve (AUC) of 76.8%. Functional assays demonstrated that circ-EGFR enhances the sensitivity to cetuximab, whereas its depletion induces resistance in CRC. Mechanistically, we revealed that circ-EGFR functions as a sponge for miR-942-3p, resulting in the upregulation of GAS1, which activates the Hedgehog signaling pathway and promotes the efficacy of cetuximab in CRC. Importantly, we effectively translated this tissue-based biomarker into a liquid biopsy predictor for anti-EGFR response (AUC: 76.9%), highlighting its non-invasive potential. In conclusion, circ-EGFR is a significant predictor of cetuximab efficacy in mCRC, potentially aiding in patient selection and treatment management, especially for patients with low circ-EGFR expression.\n                  <\/jats:p>","DOI":"10.1038\/s44321-025-00333-0","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T12:02:40Z","timestamp":1762776160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["circ-EGFR is a predictor of response to Cetuximab and a potential target in colorectal cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Silei","family":"Sui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0126-1331","authenticated-orcid":false,"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9413-5592","authenticated-orcid":false,"given":"Joan","family":"Maurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1396-6341","authenticated-orcid":false,"given":"Ajay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"333_CR1","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.neo.2018.05.004","volume":"20","author":"V Alonso","year":"2018","unstructured":"Alonso V, Escudero P, Fernandez-Martos C, Salud A, Mendez M, Gallego J, Rodriguez JR, Martin-Richard M, Fernandez-Plana J, Manzano H et al (2018) Coexpression of p-IGF-1R and MMP-7 modulates panitumumab and cetuximab efficacy in RAS wild-type metastatic colorectal cancer patients. Neoplasia 20:678\u2013686","journal-title":"Neoplasia"},{"key":"333_CR2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41575-022-00736-1","volume":"20","author":"H Bando","year":"2023","unstructured":"Bando H, Ohtsu A, Yoshino T (2023) Therapeutic landscape and future direction of metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol 20:306\u2013322","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"333_CR3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2009.24.6116","volume":"28","author":"A Bardelli","year":"2010","unstructured":"Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254\u20131261","journal-title":"J Clin Oncol"},{"key":"333_CR4","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1200\/JCO.23.01507","volume":"42","author":"F Battaglin","year":"2024","unstructured":"Battaglin F, Ou FS, Qu X, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Ashouri K, Zemla TJ, Blanke CD et al (2024) HER2 gene expression levels are predictive and prognostic in patients with metastatic colorectal cancer enrolled in CALGB\/SWOG 80405. J Clin Oncol 42:1890\u20131902","journal-title":"J Clin Oncol"},{"key":"333_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103916","volume":"183","author":"S Bhattacharya","year":"2023","unstructured":"Bhattacharya S (2023) An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer. Crit Rev Oncol Hematol 183:103916","journal-title":"Crit Rev Oncol Hematol"},{"key":"333_CR6","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.ejca.2012.02.057","volume":"48","author":"C Bokemeyer","year":"2012","unstructured":"Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Kohne CH (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:1466\u20131475","journal-title":"Eur J Cancer"},{"key":"333_CR7","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","volume":"331","author":"CL Chaffer","year":"2011","unstructured":"Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559\u20131564","journal-title":"Science"},{"key":"333_CR8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2021.02.004","volume":"505","author":"L Chen","year":"2021","unstructured":"Chen L, Shan G (2021) CircRNA in cancer: fundamental mechanism and clinical potential. Cancer Lett 505:49\u201357","journal-title":"Cancer Lett"},{"key":"333_CR9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41580-020-0243-y","volume":"21","author":"LL Chen","year":"2020","unstructured":"Chen LL (2020) The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol 21:475\u2013490","journal-title":"Nat Rev Mol Cell Biol"},{"key":"333_CR10","first-page":"2958","volume":"7","author":"F Ciardiello","year":"2001","unstructured":"Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958\u20132970","journal-title":"Clin Cancer Res"},{"key":"333_CR11","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1073\/pnas.91.5.1848","volume":"91","author":"G Del Sal","year":"1994","unstructured":"Del Sal G, Collavin L, Ruaro ME, Edomi P, Saccone S, Valle GD, Schneider C (1994) Structure, function, and chromosome mapping of the growth-suppressing human homologue of the murine gas1 gene. Proc Natl Acad Sci USA 91:1848\u20131852","journal-title":"Proc Natl Acad Sci USA"},{"key":"333_CR45","doi-asserted-by":"crossref","unstructured":"Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M (2016) CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biology 13:34\u201342","DOI":"10.1080\/15476286.2015.1128065"},{"key":"333_CR12","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1634\/theoncologist.2018-0728","volume":"24","author":"X Garcia-Albeniz","year":"2019","unstructured":"Garcia-Albeniz X, Alonso V, Escudero P, Mendez M, Gallego J, Rodriguez JR, Salud A, Fernandez-Plana J, Manzano H, Zanui M et al (2019) Prospective biomarker study in advanced RAS wild-type colorectal cancer: POSIBA trial (GEMCAD 10-02). Oncologist 24:e1115\u2013e1122","journal-title":"Oncologist"},{"key":"333_CR13","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s13402-021-00628-7","volume":"44","author":"A Georgiou","year":"2021","unstructured":"Georgiou A, Stewart A, Vlachogiannis G, Pickard L, Valeri N, Cunningham D, Whittaker SR, Banerji U (2021) A phospho-proteomic study of cetuximab resistance in KRAS\/NRAS\/BRAF(V600) wild-type colorectal cancer. Cell Oncol 44:1197\u20131206","journal-title":"Cell Oncol"},{"key":"333_CR14","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.29270","volume":"66","author":"D Han","year":"2017","unstructured":"Han D, Li J, Wang H, Su X, Hou J, Gu Y, Qian C, Lin Y, Liu X, Huang M et al (2017) Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology 66:1151\u20131164","journal-title":"Hepatology"},{"key":"333_CR15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature11993","volume":"495","author":"TB Hansen","year":"2013","unstructured":"Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J (2013) Natural RNA circles function as efficient microRNA sponges. Nature 495:384\u2013388","journal-title":"Nature"},{"key":"333_CR16","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-12-4047","volume":"73","author":"SB Keysar","year":"2013","unstructured":"Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ et al (2013) Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res 73:3381\u20133392","journal-title":"Cancer Res"},{"key":"333_CR17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.cell.2018.05.022","volume":"174","author":"B Kleaveland","year":"2018","unstructured":"Kleaveland B, Shi CY, Stefano J, Bartel DP (2018) A Network of noncoding regulatory RNAs aActs in the mammalian brain. Cell 174:350\u2013362.e317","journal-title":"Cell"},{"key":"333_CR18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41571-021-00585-y","volume":"19","author":"LS Kristensen","year":"2022","unstructured":"Kristensen LS, Jakobsen T, Hager H, Kjems J (2022) The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol 19:188\u2013206","journal-title":"Nat Rev Clin Oncol"},{"key":"333_CR19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1078-0432.CCR-18-1324","volume":"25","author":"P Laurent-Puig","year":"2019","unstructured":"Laurent-Puig P, Grisoni ML, Heinemann V, Liebaert F, Neureiter D, Jung A, Montestruc F, Gaston-Mathe Y, Thiebaut R, Stintzing S (2019) Validation of miR-31-3p expression to predict cetuximab efficacy when used as first-line treatment in RAS wild-type metastatic colorectal cancer. Clin Cancer Res 25:134\u2013141","journal-title":"Clin Cancer Res"},{"key":"333_CR20","doi-asserted-by":"crossref","first-page":"11347","DOI":"10.1073\/pnas.201418298","volume":"98","author":"CS Lee","year":"2001","unstructured":"Lee CS, Buttitta L, Fan CM (2001) Evidence that the WNT-inducible growth arrest-specific gene 1 encodes an antagonist of sonic hedgehog signaling in the somite. Proc Natl Acad Sci USA 98:11347\u201311352","journal-title":"Proc Natl Acad Sci USA"},{"key":"333_CR21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/bjs.5278","volume":"93","author":"J Leporrier","year":"2006","unstructured":"Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G (2006) A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 93:465\u2013474","journal-title":"Br J Surg"},{"key":"333_CR22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.trecan.2020.01.012","volume":"6","author":"J Li","year":"2020","unstructured":"Li J, Sun D, Pu W, Wang J, Peng Y (2020) Circular RNAs in cancer: biogenesis, function, and clinical significance. Trends Cancer 6:319\u2013336","journal-title":"Trends Cancer"},{"key":"333_CR23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1158\/0008-5472.CAN-22-2585","volume":"83","author":"X Li","year":"2023","unstructured":"Li X, Wang C, Zhang H, Li Y, Hou D, Liu D, Xu R, Cheng J, Liu L, Fu Y et al (2023) circFNDC3B accelerates vasculature formation and metastasis in oral squamous cell carcinoma. Cancer Res 83:1459\u20131475","journal-title":"Cancer Res"},{"key":"333_CR24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.molcel.2018.06.034","volume":"71","author":"X Li","year":"2018","unstructured":"Li X, Yang L, Chen LL (2018) The biogenesis, functions, and challenges of circular RNAs. Mol Cell 71:428\u2013442","journal-title":"Mol Cell"},{"key":"333_CR25","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/neuonc\/noaa279","volume":"23","author":"Y Liu","year":"2021","unstructured":"Liu Y, Li Z, Zhang M, Zhou H, Wu X, Zhong J, Xiao F, Huang N, Yang X, Zeng R et al (2021) Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity. Neuro Oncol 23:743\u2013756","journal-title":"Neuro Oncol"},{"key":"333_CR26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/nm.4424","volume":"23","author":"Y Lu","year":"2017","unstructured":"Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z, Singh B, Franklin JL, Wang J, Hu H et al (2017) lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt\/beta-catenin signaling. Nat Med 23:1331\u20131341","journal-title":"Nat Med"},{"key":"333_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00289","volume":"3","author":"J Maurel","year":"2019","unstructured":"Maurel J, Alonso V, Escudero P, Fernandez-Martos C, Salud A, Mendez M, Gallego J, Rodriguez JR, Martin-Richard M, Fernandez-Plana J et al (2019) Clinical impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer treated with first-line chemotherapy plus anti-epidermal growth factor receptor therapy. JCO Precis Oncol 3:1\u201316","journal-title":"JCO Precis Oncol"},{"key":"333_CR28","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G et al (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532\u2013536","journal-title":"Nature"},{"key":"333_CR29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbrc.2016.07.090","volume":"478","author":"H Mo","year":"2016","unstructured":"Mo H, He J, Yuan Z, Mo L, Wu Z, Lin X, Liu B, Guan J (2016) WT1 is involved in the Akt-JNK pathway dependent autophagy through directly regulating Gas1 expression in human osteosarcoma cells. Biochem Biophys Res Commun 478:74\u201380","journal-title":"Biochem Biophys Res Commun"},{"key":"333_CR30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN, Benson 3rdAB, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming DA et al (2023) Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 41:678\u2013700","journal-title":"J Clin Oncol"},{"key":"333_CR31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41011-4","volume":"14","author":"AJ Ohnmacht","year":"2023","unstructured":"Ohnmacht AJ, Stahler A, Stintzing S, Modest DP, Holch JW, Westphalen CB, Holzel L, Schubel MK, Galhoz A, Farnoud A et al (2023) The oncology biomarker discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer. Nat Commun 14:5391","journal-title":"Nat Commun"},{"key":"333_CR32","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/nrd2086","volume":"5","author":"LL Rubin","year":"2006","unstructured":"Rubin LL, de Sauvage FJ (2006) Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 5:1026\u20131033","journal-title":"Nat Rev Drug Discov"},{"key":"333_CR33","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1158\/0008-5472.CAN-08-2331","volume":"69","author":"H Schnidar","year":"2009","unstructured":"Schnidar H, Eberl M, Klingler S, Mangelberger D, Kasper M, Hauser-Kronberger C, Regl G, Kroismayr R, Moriggl R, Sibilia M et al (2009) Epidermal growth factor receptor signaling synergizes with Hedgehog\/GLI in oncogenic transformation via activation of the MEK\/ERK\/JUN pathway. Cancer Res 69:1284\u20131292","journal-title":"Cancer Res"},{"key":"333_CR34","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1053\/j.gastro.2022.02.017","volume":"162","author":"X Shi","year":"2022","unstructured":"Shi X, Yang J, Liu M, Zhang Y, Zhou Z, Luo W, Fung KM, Xu C, Bronze MS, Houchen CW et al (2022) Circular RNA ANAPC7 inhibits tumor growth and muscle wasting via PHLPP2-AKT-TGF-beta signaling axis in pancreatic cancer. Gastroenterology 162:2004\u20132017.e2002","journal-title":"Gastroenterology"},{"key":"333_CR35","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","volume":"26","author":"AF Sobrero","year":"2008","unstructured":"Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311\u20132319","journal-title":"J Clin Oncol"},{"key":"333_CR36","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.3390\/ijms15045838","volume":"15","author":"N Song","year":"2014","unstructured":"Song N, Liu S, Zhang J, Liu J, Xu L, Liu Y, Qu X (2014) Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells. Int J Mol Sci 15:5838\u20135851","journal-title":"Int J Mol Sci"},{"key":"333_CR37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/annonc\/mdu378","volume":"26","author":"MJ Sorich","year":"2015","unstructured":"Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26:13\u201321","journal-title":"Ann Oncol"},{"key":"333_CR38","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.22.02582","volume":"41","author":"A Stahler","year":"2023","unstructured":"Stahler A, Hoppe B, Na IK, Keilholz L, Muller L, Karthaus M, Fruehauf S, Graeven U, Fischer von Weikersthal L, Goekkurt E et al (2023) Consensus molecular subtypes as biomarkers of fluorouracil and folinic acid maintenance therapy with or without panitumumab in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212). J Clin Oncol 41:2975\u20132987","journal-title":"J Clin Oncol"},{"key":"333_CR39","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"333_CR40","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386\u20131422","journal-title":"Ann Oncol"},{"key":"333_CR41","volume":"21","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wu C, Du Y, Li Z, Li M, Hou P, Shen Z, Chu S, Zheng J, Bai J (2022) Expanding uncapped translation and emerging function of circular RNA in carcinomas and noncarcinomas. Mol Cancer 21:13","journal-title":"Mol Cancer"},{"key":"333_CR44","doi-asserted-by":"crossref","unstructured":"Wierbowski BM, Petrov K, Aravena L, Gu G, Xu Y, Salic A (2020) Hedgehog Pathway Activation Requires Coreceptor-Catalyzed, Lipid-Dependent Relay of the Sonic Hedgehog Ligand. Developmental Cell 55:450\u2013467.e8","DOI":"10.1016\/j.devcel.2020.09.017"},{"key":"333_CR42","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1078-0432.CCR-24-1934","volume":"31","author":"C Xu","year":"2025","unstructured":"Xu C, Mannucci A, Esposito F, Oliveres H, Alonso-Orduna V, Yubero A, Fernandez-Martos C, Salud A, Gallego J, Martin-Richard M et al (2025) An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: the EXONERATE study. Clin Cancer Res 31:1002\u20131015","journal-title":"Clin Cancer Res"},{"key":"333_CR43","volume":"17","author":"C Yang","year":"2018","unstructured":"Yang C, Yuan W, Yang X, Li P, Wang J, Han J, Tao J, Li P, Yang H, Lv Q et al (2018) Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17\/miR-224 and regulating p21, PTEN expression. Mol Cancer 17:19","journal-title":"Mol Cancer"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00333-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-025-00333-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00333-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:32Z","timestamp":1786985252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-025-00333-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,8]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1038\/s44321-025-00333-0","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"12"}}